Company / Cash per Share
Fulcrum Therapeutics, Inc. Cash per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$3117.88
FY2025
5-year range
$416.95 / $3117.88
FY2021-FY2025
Trend
+232.0%
vs FY2024
Sector context
#2 of 205
Health Care
What the data says
Cash per Share changed +232% YoY in FY2025, a notable deviation from the 7-year average annual change of +11%.
Based on SEC 10-K filings.
3117.88 in FY2025 with a 5-year CAGR of +6.7%. Ranks 2nd among 205 companies in Health Care.
Improved from $416.95 to $3117.88 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +58.7%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 205This company $3117.88 Sector average $72.93
▼
+4175.1% above sector average
Key checks
Key Insights
- In FY2025, cash per share increased 232.0% year-over-year.
- Ranks #2 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2018.
- Lowest cash per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3117.88 | +232.0% |
| FY2024 | $939.15 | +125.2% |
| FY2023 | $416.95 | -46.6% |
| FY2022 | $780.11 | -22.1% |
| FY2021 | $1001.44 | -55.5% |
| FY2020 | $2250.22 | -74.3% |
| FY2019 | $8755.48 | -84.9% |
| FY2018 | $57913.29 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026